Faculty of Pharmaceutical Sciences, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
Laboratory for Biological Drug Development based on DDS Technology, Hokkaido University, Kita-12, Nishi-6, Kita-ku, Sapporo 060-0812, Japan.
Int J Mol Sci. 2020 Sep 2;21(17):6365. doi: 10.3390/ijms21176365.
Mitochondrial transplantation therapy is an innovative strategy for the treatment of mitochondrial dysfunction. The approach has been reported to be useful in the treatment of cardiac ischemic reperfusion injuries in human clinical trials and has also been shown to be useful in animal studies as a method for treating mitochondrial dysfunction in various tissues, including the heart, liver, lungs, and brain. On the other hand, there is no methodology for using preserved mitochondria. Research into the pharmaceutical formulation of mitochondria to promote mitochondrial transplantation therapy as the next step in treating many patients is urgently needed. In this review, we overview previous studies on the therapeutic effects of mitochondrial transplantation. We also discuss studies related to immune responses that occur during mitochondrial transplantation and methods for preserving mitochondria, which are key to their stability as medicines. Finally, we describe research related to mitochondrial targeting drug delivery systems (DDS) and discuss future perspectives of mitochondrial transplantation.
线粒体移植治疗是一种治疗线粒体功能障碍的创新策略。该方法已在人体临床试验中被报道可用于治疗心脏缺血再灌注损伤,并且在动物研究中也被证明是治疗心脏、肝脏、肺和脑等各种组织中线粒体功能障碍的有效方法。另一方面,目前没有使用保存线粒体的方法。急需研究将线粒体制成药物配方以促进线粒体移植治疗,作为下一步治疗许多患者的方法。在这篇综述中,我们概述了以前关于线粒体移植治疗效果的研究。我们还讨论了与线粒体移植过程中发生的免疫反应以及保存线粒体的方法相关的研究,这些方法是将线粒体作为药物稳定存在的关键。最后,我们描述了与线粒体靶向药物传递系统(DDS)相关的研究,并讨论了线粒体移植的未来展望。